Welcome to our dedicated page for INTENSITY THERAPEUTICS SEC filings (Ticker: INTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intensity Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing intratumoral cancer therapies led by INT230-6. Form 8-K reports furnish operating results, financial-condition updates, investor-presentation materials, and clinical-development summaries tied to the company’s non-covalent drug-conjugation platform and oncology studies.
The filing record also covers capital-structure and public-company matters, including an at-the-market common stock offering program, amendments related to a reverse stock split, Nasdaq minimum-bid-price compliance, and modifications to security-holder rights. Proxy materials describe annual meeting proposals, board elections, independent auditor ratification, and amendments to equity compensation and employee stock purchase plans.
Intensity Therapeutics, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing requirement. Nasdaq confirmed that the company’s common stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from February 19, 2026 through March 4, 2026, and the matter is now closed.
The company had previously received Nasdaq deficiency notices in June and December 2025 after its share price stayed below $1.00, and was given until June 1, 2026 to regain compliance. Intensity also issued a press release describing its late-stage clinical focus and lead intratumoral cancer therapy candidate INT230-6, which is being evaluated in multiple Phase 2 and Phase 3 studies.
Intensity Therapeutics, Inc. furnished an update to its investor materials, providing an unaudited Financial Highlights Slide through December 31, 2025. The slide, dated March 4, 2026, is available on the company’s investor relations website and is also attached as an exhibit.
The figures in this slide are preliminary and subject to completion of financial closing procedures and management review, so they may differ materially from the final results reported in the company’s year-end financial statements.
Intensity Therapeutics, Inc. approved and implemented a 1-for-25 reverse stock split of its common stock to take legal effect at 4:01 p.m. Eastern Time on February 18, 2026. The shares are expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market on February 19, 2026 under the existing ticker INTS but with a new CUSIP 45828J 202.
Every 25 issued and outstanding shares will be converted into 1 share, with no change to the total number of authorized shares. Fractional shares will not be issued; instead, affected stockholders will receive cash based on the February 18, 2026 closing price. The company estimates that outstanding shares will decrease from approximately 63,346,579 as of February 12, 2026 to approximately 2,533,863, with proportional adjustments to stock options, warrants, convertible securities and equity plan share counts.
Intensity Therapeutics (INTS) furnished an Item 2.02 8‑K announcing its financial results for the three and nine months ended September 30, 2025. The company released the details via a press release attached as Exhibit 99.1. The information is being furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings except as expressly set forth by specific reference.
The 8‑K reiterates standard forward‑looking statement cautions and points readers to the company’s Form 10‑K and recent Form 10‑Qs for risk factors and additional context.
Intensity Therapeutics (NASDAQ: INTS) filed its Q3 2025 10‑Q, showing lower operating spend and continued reliance on equity financing while advancing its clinical programs. Cash and cash equivalents were $7.1 million as of September 30, 2025, up from $2.6 million at year‑end, driven by an at‑the‑market program and public offerings. Q3 net loss was $2.7 million with operating expenses of $2.7 million as R&D and G&A declined year over year. For the nine months, net loss totaled $8.6 million and operating cash use was $6.8 million.
The company paused enrollment in its Phase 3 INVINCIBLE‑3 sarcoma study in March 2025 due to funding constraints and paused new enrollment in the Phase 2 INVINCIBLE‑4 TNBC study in September 2025 to revise dosing. Subsequent to quarter‑end, INTS raised $2.0 million net via ATM and $4.0 million gross in a registered direct offering. Management states available capital is expected to fund current operations until the end of the first quarter of 2027, yet the filing notes substantial doubt about continuing as a going concern given the need for additional financing. Shares outstanding were 49,068,621 as of September 30, 2025; 60,064,965 as of November 5, 2025.
Intensity Therapeutics (INTS) launched a primary offering of 5,000,000 shares of common stock directly to an institutional investor at $0.80 per share under a Rule 424(b)(5) prospectus supplement. Gross proceeds are $4.0 million, with a 7.0% placement fee to A.G.P./Alliance Global Partners and estimated net proceeds of approximately $3.6 million after fees and expenses.
The company plans to use the funds for the advancement of clinical trials, working capital and general corporate purposes. This is a reasonable best efforts transaction; A.G.P. is acting as sole placement agent and is not purchasing the securities. Delivery is expected on or about November 3, 2025. Shares outstanding were 54,998,965 as of October 30, 2025, and are expected to be 59,998,965 after the offering. INTS last closed at $1.32 per share on October 30, 2025.
Intensity Therapeutics (INTS) entered a securities purchase agreement for a registered direct offering of 5,000,000 shares of common stock at $0.80 per share, for $4.0 million in aggregate gross proceeds. The shares are being offered off the company’s Form S-3 (File No. 333-280681), declared effective on July 11, 2024.
The transaction is expected to close on or about November 3, 2025, subject to customary closing conditions. The company engaged A.G.P./Alliance Global Partners as placement agent and agreed to pay a cash fee equal to 7.0% of gross proceeds and reimburse documented out-of-pocket expenses, including legal fees up to $50,000. The purchase agreement includes customary terms and a 30-day restriction on issuing or selling additional common stock or common stock equivalents following closing.
On October 31, 2025, the company announced pricing via a press release incorporated as an exhibit.
Intensity Therapeutics (INTS) reported voting results from its October 22, 2025 special meeting. Stockholders approved an amendment allowing a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-30. The board may set the exact ratio in its sole discretion, may choose not to effect the split, and the action will not reduce the authorized number of common shares.
A quorum was present with 22,869,562 shares represented, or 46.61% of shares entitled to vote. Proposal 1 (reverse split authorization) passed with 18,333,570 For, 4,508,502 Against, and 27,490 Abstain. Proposal 2 (potential adjournment) was also approved with 18,869,741 For, 3,893,779 Against, and 106,042 Abstain.
Intensity Therapeutics reported an update on its INVINCIBLE-4 study involving its drug candidate INT230-6. The company observed a pathological complete response in the first patient evaluated in Cohort A, where patients receive two doses of INT230-6 eight days apart followed by standard immunochemotherapy. The company stated that, to date, the safety profile in Cohort A looks favorable, although some patients experienced localized skin irritation near the tumor site. Because of these local skin effects, new patient enrollment in Cohort A has been paused while the team evaluates the collected data and implements any necessary protocol adjustments before reopening enrollment.
Intensity Therapeutics (INTS) is soliciting stockholder approval for an amendment to implement a Reverse Stock Split and an adjournment proposal. As of the Record Date there were 49,055,462 shares outstanding; a quorum requires holders of at least 16,351,821 shares. The proposed Reverse Stock Split would proportionally reduce outstanding shares to between 9,811,092 and 1,635,182 shares depending on the split ratio chosen, and would increase the number of authorized but unissued shares. The board unanimously recommends a vote FOR the Amendment Proposal.
The proxy explains effects on fractional shares (cash paid in lieu), adjustments to options/warrants, no change to par value ($0.0001), and potential dilution from future issuances. The company notes capital needs and intends to seek additional financing, including an At-The-Market agreement with H.C. Wainwright. The filing summarizes U.S. federal income tax consequences, including that cash for fractions may generate capital gain or backup withholding.